Evaluating Beta-blocker Continuation Versus Temporary Interruption in Patients Undergoing Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis
Led by National and Kapodistrian University of Athens · Updated on 2026-10-20
348
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of continuing versus temporarily stopping chronic beta-blocker therapy in patients undergoing transcatheter aortic valve implantation TAVI for severe symptomatic aortic stenosis. This prospective, multicenter, randomized trial compares two strategies to understand their impact on conduction disturbances and the need for permanent pacemakers after TAVI. The study addresses an important clinical question as beta-blockers may affect heart rhythm during this procedure, and current evidence is inconclusive.
Participants are randomly assigned to either continue their prescribed beta-blocker medication starting at least 72 hours before TAVI through 7 days after the procedure, or to temporarily stop beta-blocker therapy during this period. Dose adjustments or early reinitiation of beta-blockers are allowed if medically necessary. All TAVI procedures follow standard care, and decisions about pacemaker implantation are made independently of treatment assignment.
During the study, participants will be monitored with clinical and electrocardiographic assessments at baseline, during hospitalization, at discharge, and at 7 days, 30 days, and 12 months after TAVI. Researchers will measure the rate of new permanent pacemaker implantation within 7 days as the primary outcome and will also track heart rhythm disturbances, arrhythmias, hemodynamic changes, mortality, and treatment adherence. Follow-up continues up to one year to evaluate longer-term effects and safety.
CONDITIONS
Brief Title
Impact of Beta Blockers on TAVI (BETA-TAVI)
Research Team
L
Leonidas Koliastasis, MD, MSc, PhD
O
Odysseas Katsaros, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Severe symptomatic aortic stenosis defined by specific heart valve measurements
Suitable for TAVI confirmed by a multidisciplinary Heart Team
Currently taking oral beta-blockers for a recognized clinical reason
Ability and willingness to follow the assigned treatment and follow-up schedule
Provide written informed consent before any trial procedure
You will not qualify if you...
Existing permanent pacemaker or other cardiac rhythm device
Certain advanced heart conduction blocks unless a pacemaker is already needed
Resting heart rate below 50 beats per minute at screening
Medical condition requiring mandatory continuation or withdrawal of beta-blockers
Active infection including infective endocarditis
Blood clots in the heart detected by imaging
Contraindications to required antithrombotic treatment for TAVI
Known allergies to procedural drugs, contrast media, or device components
Life expectancy under 12 months due to non-cardiac disease
Pregnancy or potential for pregnancy without reliable contraception
Conditions preventing reliable assessment of primary endpoint or follow-up
Participation in another interventional study that may interfere with this trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - Approximately 10 days
Participants are randomly assigned to either continue their beta-blocker medication or temporarily stop taking it from at least 72 hours before TAVI through 7 days after the procedure. Dose modifications are allowed if medically necessary.
Daily monitoring from 3 days before to 7 days after TAVI
Follow-up
Duration - 12 months
Participants will have clinical and heart rhythm assessments at discharge, 7 days, 30 days, and 12 months after TAVI to monitor outcomes including pacemaker implantation and arrhythmias.
4 follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Prospective Study to Collect CT Imaging and Echocardiography Data for Predicting Outcomes After Transcatheter Aortic Valve Implantation
Evaluating Safety and Effectiveness of the Edwards SAPIEN X4 Balloon-Expandable Transcatheter Heart Valve for Treating Failing Aortic Bioprosthetic Valves
Study of Angiotensin Receptor Blockers to Slow Progression of Mild to Moderate Aortic Stenosis and Improve Heart Function
Heparin Reversal With Protamine Sulfate to Reduce Complications After Transcatheter Aortic Valve Replacement for Aortic Stenosis
Comparing Transcatheter and Surgical Aortic Valve Replacement in Patients Over 50 with Severe Aortic Valve Narrowing and Bicuspid Valve
Evaluating the EmStop Embolic Protection System Compared to the Sentinel Device During Self-Expanding Transcatheter Aortic Valve Replacement for Aortic Valve Stenosis
CardioHeartConnect Mobile Cardiac Rehabilitation Using Peloton Fitness Modules
Compared to Educational Materials for Patients Recovering from Transcatheter Aortic Valve Replacement
Clinical Outcomes and Valve Performance After Transcatheter Aortic Valve Replacement in Adults with Severe Aortic Valve Disease
Feasibility and Safety Study of the Point-Guard Embolic Protection Device During Transcatheter Aortic Valve Replacement TAVR
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Authors/Task Force members, Perry M Elliott, Aris Anastasakis...
2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).
Josep Brugada, Demosthenes G Katritsis, Elena Arbelo...
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres...